• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Celularity Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    5/9/25 4:30:11 PM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CELU alert in real time by email
    false 0001752828 0001752828 2025-05-09 2025-05-09 0001752828 CELU:ClassCommonStock0.0001ParValuePerShareMember 2025-05-09 2025-05-09 0001752828 CELU:WarrantsEachExercisableForOnetenthOfOneShareOfClassCommonStockAtExercisePriceOf11.50PerShareMember 2025-05-09 2025-05-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): May 9, 2025

     

     

     

    Celularity Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-38914   83-1702591

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    170 Park Ave

    Florham Park, New Jersey

      07932
    (Address of principal executive offices)   (Zip Code)

     

    Registrant’s telephone number, including area code: (908) 768-2170

     

    N/A

    (Former name or former address, if changed since last report.)

     

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Class A Common Stock, $0.0001 par value per share   CELU   The Nasdaq Stock Market LLC
    Warrants, each exercisable for one-tenth of one share of Class A Common Stock at an exercise price of $11.50 per share   CELUW   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     
     

     

    Item 2.02 Results of Operations and Financial Condition.

     

    On May 9, 2025, Celularity Inc. issued a press release announcing operating and financial results for the year ended December 31, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.

     

    The information in this report, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. In addition, the exhibit furnished herewith contain statements intended as “forward-looking statements” that are subject to the cautionary statements about forward-looking statements set forth in such exhibit.

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits

     

    Exhibit No.   Description
    99.1   Press Release of Celularity Inc. dated May 9, 2025
    104   Cover Page Interactive Data File (Embedded within the Inline XBRL document)

     

    -2-
     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      CELULARITY INC.
    Dated: May 9, 2025  
      By:

    /s/ Robert J. Hariri

      Name: Robert J. Hariri, M.D., Ph.D.
      Title: Chairman and CEO

     

    -3-

     

    Get the next $CELU alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CELU

    DatePrice TargetRatingAnalyst
    1/30/2023$5.00 → $1.00Equal-Weight → Underweight
    Morgan Stanley
    12/22/2022Outperform → Perform
    Oppenheimer
    6/22/2022$15.00Buy
    H.C. Wainwright
    4/6/2022$10.00Buy → Hold
    Truist
    1/28/2022$9.00Outperform
    Oppenheimer
    11/24/2021$9.00Equal-Weight
    Morgan Stanley
    10/19/2021$12.00Buy
    Truist Securities
    More analyst ratings

    $CELU
    Leadership Updates

    Live Leadership Updates

    See more
    • Celularity Appoints Richard J. Berman to its Board of Directors

      FLORHAM PARK, N.J., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) (the "Company"), a regenerative and cellular medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, announced today the appointment of Richard J. Berman, to its Board of Directors. Mr. Berman is an experienced public company director whose career spans over 40 years of venture capital, senior management, and merger and acquisitions experience. He has served as a director and/or officer of over a dozen public and private companies in the last five years, six of which have reached over one billion dollars in market value. Previously, Mr. Berman worked at Gol

      8/28/24 4:45:00 PM ET
      $CELU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Celularity Appoints Geoffrey Shiu Fei Ling, M.D., Ph.D. to its Board of Directors

      FLORHAM PARK, N.J., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) (Celularity), a biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies and advanced biomaterial products, today announced the appointment of Geoffrey Shiu Fei Ling, M.D., Ph.D. to its Board of Directors. Dr. Ling, a distinguished academic and military physician-scientist with a strong background in regenerative medicine and a deep commitment to advancing healthcare, will bring invaluable expertise and insights to Celularity as it continues to pioneer innovative therapies for patients in need. Throughout his career, Dr. Ling has made significant contributions to regenera

      9/7/23 4:10:00 PM ET
      $CELU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Celularity Appoints Paul Graves as Chief Communications Officer

      FLORHAM PARK, N.J., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a biotechnology company developing placental-derived allogeneic cell and biomaterial therapies, today announced that Paul Graves has been appointed Senior Vice President, Chief Communications Officer, effective January 2, 2023. Mr. Graves is a seasoned communications professional who brings more than 30 years of strategic communications experience in the biopharmaceutical industry. He has deep expertise in corporate reputation, global research and development, product launch and promotion, investor relations and public affairs. He will provide senior strategic communications leadership for C

      1/4/23 4:10:00 PM ET
      $CELU
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CELU
    SEC Filings

    See more
    • Celularity Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Celularity Inc (0001752828) (Filer)

      5/9/25 4:30:11 PM ET
      $CELU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by Celularity Inc.

      10-K - Celularity Inc (0001752828) (Filer)

      5/8/25 5:28:42 PM ET
      $CELU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Celularity Inc. filed SEC Form 8-K: Other Events

      8-K - Celularity Inc (0001752828) (Filer)

      5/1/25 4:15:23 PM ET
      $CELU
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CELU
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Celularity Inc. (Amendment)

      SC 13D/A - Celularity Inc (0001752828) (Subject)

      3/15/24 5:32:04 PM ET
      $CELU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Celularity Inc. (Amendment)

      SC 13G/A - Celularity Inc (0001752828) (Subject)

      2/8/24 6:00:11 AM ET
      $CELU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Celularity Inc. (Amendment)

      SC 13D/A - Celularity Inc (0001752828) (Subject)

      1/17/24 5:15:41 PM ET
      $CELU
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CELU
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Lim Kok Thay bought $5,331,335 worth of shares (21,410,983 units at $0.25) (SEC Form 4)

      4 - Celularity Inc (0001752828) (Issuer)

      1/17/24 5:22:20 PM ET
      $CELU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Hariri Robert J bought $2,984,294 worth of shares (18,422,124 units at $0.16), increasing direct ownership by 182% to 28,570,434 units (SEC Form 4)

      4 - Celularity Inc (0001752828) (Issuer)

      10/10/23 9:48:11 PM ET
      $CELU
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CELU
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Celularity downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Celularity from Equal-Weight to Underweight and set a new price target of $1.00 from $5.00 previously

      1/30/23 7:11:17 AM ET
      $CELU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Celularity downgraded by Oppenheimer

      Oppenheimer downgraded Celularity from Outperform to Perform

      12/22/22 7:40:17 AM ET
      $CELU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on Celularity with a new price target

      H.C. Wainwright initiated coverage of Celularity with a rating of Buy and set a new price target of $15.00

      6/22/22 7:19:25 AM ET
      $CELU
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CELU
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Pres., Functional Regeneration Brigido Stephen converted options into 820 shares and covered exercise/tax liability with 268 shares, increasing direct ownership by 7% to 8,921 units (SEC Form 4)

      4 - Celularity Inc (0001752828) (Issuer)

      4/15/25 4:30:29 PM ET
      $CELU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Hariri Robert J converted options into 3,281 shares and covered exercise/tax liability with 1,154 shares, increasing direct ownership by 12% to 20,328 units (SEC Form 4)

      4 - Celularity Inc (0001752828) (Issuer)

      4/15/25 4:30:27 PM ET
      $CELU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Beers David C converted options into 1,025 shares and covered exercise/tax liability with 360 shares, increasing direct ownership by 4% to 18,201 units (SEC Form 4)

      4 - Celularity Inc (0001752828) (Issuer)

      4/15/25 4:30:24 PM ET
      $CELU
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CELU
    Financials

    Live finance-specific insights

    See more

    $CELU
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Celularity Provides Corporate Update

      FLORHAM PARK, N.J., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a regenerative and cellular medicine company, has issued a Corporate Update to Shareholders from Robert J. Hariri, M.D., Ph.D., Founder, Chairman, and CEO. Dear Shareholders, I am pleased to share recent developments at Celularity, including an update on our commercial-stage advanced biomaterial products business. Let me start by reiterating what we said in our announcement last week, which is that we are resolutely committed to regaining full compliance with Nasdaq's listing requirements. We acknowledge the importance of timely filings and have been diligently working with our new auditi

      10/22/24 8:30:00 AM ET
      $CELU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Celularity Announces Full Year 2024 Operating and Financial Results

      FLORHAM PARK, N.J., May 09, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity" or the "Company"), a regenerative and cellular medicine company, today announced operating and financial results for the year ended December 31, 2024. "We built momentum through 2024 and ended the year with a strong finish, as reflected in higher net revenues from the sale of our commercial-stage advanced biomaterial products," said Dr. Robert Hariri, M.D., Ph.D., CEO and Chairman. "Sales growth was notably strong for our Biovance® product line, which we believe will continue to contribute to an improving revenue outlook for the next several quarters. We were also extremely pleased to receive

      5/9/25 9:15:00 AM ET
      $CELU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Celularity Receives Nasdaq Notice Regarding Non-Payment of Nasdaq Fees

      FLORHAM PARK, N.J., April 25, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity" or the "Company"), a cellular and regenerative medicine company, today announced that Nasdaq has notified the Company that it has not paid certain fees required by Listing Rule 5250(f) and accordingly the Company will be delisted unless it appeals this determination. The Company's past due fee balance totaled $70,000. On April 25, 2025, the Company paid in full the fee balance owed to Nasdaq. Additionally, on April 16, 2024, Nasdaq notified the Company that it is delinquent in filing its Form 10-K for the year ended December 31, 2024, and therefore, does not comply with Listing Rule 5250(c)(

      4/25/25 5:30:00 PM ET
      $CELU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Celularity Welcomes CMS Action on Medicare Local Coverage Determination for Skin Substitutes Products

      FLORHAM PARK, N.J., April 14, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity" or the "Company"), a regenerative and cellular medicine company, welcomes action by the Centers for Medicare & Medicaid Services, or CMS, to revise to January 1, 2026, the effective date of the Medicare Local Coverage Determination, or LCD, titled "Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers" first published in November 2024. An LCD is a determination by a Medicare Administrative Contractor, or MAC, whether to cover a particular service on a MAC-wide, basis. A MAC processes Medicare Part A and Part B claims for a d

      4/14/25 8:00:00 AM ET
      $CELU
      Biotechnology: Pharmaceutical Preparations
      Health Care